EBITDA: Income before interest, taxes, depreciation and amortization.
ReShape Lifesciences Inc. (RSLS) had EBITDA of $-2.20M for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
$1.11M |
|
$1.47M |
|
$0.43M |
|
$0.68M |
|
$3.32M |
|
$-2.21M |
|
$3.69M |
|
$1.48M |
|
$1.48M |
|
$1.47M |
|
$1.47M |
|
$1.47M |
|
$1.47M |
|
$-2.21M |
|
|
EBITDA |
$-2.20M |
0.08M |
|
0.08M |
|
$18.98 |
|
$18.98 |
|
| Balance Sheet Financials | |
$6.29M |
|
$0.03M |
|
$0.19M |
|
$6.48M |
|
$4.12M |
|
-- |
|
$1.13M |
|
$5.25M |
|
$1.23M |
|
$1.23M |
|
$1.23M |
|
0.13M |
|
| Cash Flow Statement Financials | |
$-2.12M |
|
-- |
|
$3.95M |
|
$0.79M |
|
$2.62M |
|
$1.82M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.53 |
|
-- |
|
-- |
|
-- |
|
-- |
|
61.19% |
|
-198.20% |
|
-198.20% |
|
-- |
|
133.06% |
|
132.43% |
|
$-2.12M |
|
-- |
|
-- |
|
-- |
|
0.17 |
|
0.17 |
|
1.52 |
|
59.35 |
|
119.83% |
|
119.84% |
|
22.74% |
|
119.84% |
|
$9.25 |
|
$-27.17 |
|
$-27.17 |
|